

Guangzhou Saliat Stem Cell Science and Technology Co., Ltd.

Guangzhou Saliat Stem Cell Science and Technology Co., Ltd. (“Saliat”) is a nationally-leading innovative enterprise specializing in stem-cell research, preparation, storage and new-drug R&D. Founded in 2009, it is the first stem-cell enterprise listed on the National Equities Exchange and Quotations (NEEQ) with the stock code 831049. Headquartered on Guangzhou International Bio-Island, the company has a registered capital of RMB 250 million. Driven by core stem-cell technologies, it is a national high-tech enterprise integrating biomedicine R&D, cell storage, health management and industrial application. Upholding its mission of “Science and Love Guarding Life”, Saliat commits to advancing the cause of human health through stem-cell science and technological innovation.

Led by Dr. Chen Haijia, a recipient of the National leading tech entrepreneurs, State Council Special Allowance expert and researcher in cell biology, Saliat has built a strong R&D team with Academician Su Guohui from the Chinese Academy of Sciences serving as Chief Scientist. The company has been approved to establish National Enterprise Technology Center in the stem-cell sector, Guangdong Province’s sole provincial-level Regional Cell Preparation Center, as well as a Stem-Cell Academician Workstation, National Postdoctoral Research Workstation, Guangdong Engineering Technology Research Center for Stem-Cell Storage and Clinical Application, and

Guangdong Stem-Cell Preparation Engineering Laboratory and other innovation platforms.

Saliai has undertaken more than 40 key national R&D programs and major provincial-municipal scientific research projects. It has overcome core bottleneck technologies in stem-cell field and obtained over 300 authorized patents related to stem cells, ranking first among domestic enterprises in this sector. Its total number of patent applications for stem-cell preparation, collection and cryopreservation technologies ranks among the world's top, winning 5 China Patent Excellence Awards. The independently-developed Class-1 innovative drug, human umbilical cord-derived mesenchymal stem cells for knee osteoarthritis treatment, is Guangdong's first Class-1 stem-cell new drug approved for clinical trials and has entered Phase-II clinical trial. Multiple joint stem-cell clinical studies have yielded positive outcomes, including stem-cell therapies for knee osteoarthritis, infertility, ischemic stroke and neuromyelitis optica.

As a leading national innovative stem-cell enterprise, Saliai serves as the president-unit of the Stem-Cell and Precision Medicine Quality Management Branch of China Pharmaceutical Quality Management Association and Guangdong Stem Cell and Regenerative Medicine Association. It has hosted the annual International (Guangzhou) Industrialization Conference on Stem Cells and Precision Medicine for 11 consecutive years, set up the Guangdong-Hong Kong-Macao Greater Bay Area Stem-Cell Industry Alliance to boost

international exchanges and cooperation, formulate industrial standards and promote high-quality development of the stem-cell industry.

The company has received numerous honors, including National Intellectual Property Advantage Enterprise, China Patent Excellence Award, Top 100 China Sci-Tech Innovation Enterprises, Leading Enterprise of China's Stem-Cell Industry, Top 100 Innovative Enterprises on China's NEEQ, Listed Enterprise on the Top 100 Most Influential Chinese Pharmaceutical Enterprises, and No.1 of Guangdong NEEQ Innovative TOP50 Enterprises.

广州赛莱拉干细胞科技股份有限公司企业简介

广州赛莱拉干细胞科技股份有限公司（简称“赛莱拉”）是一家专注干细胞研究、制备、储存及新药研发的全国领先的干细胞创新型企业，成立于2009年，新三板干细胞第一股（股票代码831049），总部位于广州国际生物岛，注册资本2.5亿元，是一家以干细胞核心技术驱动，集生物医药研发、细胞储存、健康管理及产业化应用于一体的国家高新技术企业。公司秉承“科学和爱，守护生命”的使命，致力于通过干细胞科技与创新，推动人类健康事业发展。

在国家“万人计划”科技创业领军人才、国务院津贴专家、细胞生物学研究员陈海佳博士带领下，组建了以中国科学院苏国辉院士作为首席科学家的实力雄厚的科研团队，获批建设有干细胞领域全国唯一的国家企业技术中心、广东省唯一的省级区域细胞制备中心，成立了干细胞院士工作站、国家博士后科研工作站、广东省干细胞储存和临床应用工程技术研究中心、广东省干细胞制备工程实验室等创新平台。公司承担国家重点研发、省市重大科研项目40多项，攻克干细胞卡脖子技术，获得干细胞相关授权专利300多项，位列干细胞技术领域全国企业第一位，干细胞制备技术、采集冻存技术专利申请总量位居全球前列，获得5项中国发明专利优秀奖。自主研发的国家1类创新药——人脐带间充质干细胞治疗膝骨关节炎是广东省首个获批临床试验的干细胞国家1类新药，已进入II期临床试验，并联合开展“干细胞治疗膝骨关节炎”“干细胞治疗不孕症”“干细胞治疗缺血性脑卒中”“干细胞治疗视神经脊髓炎”等多项干细胞临床研究取得积极成果。

作为全国领先的干细胞创新型企业，公司担任中国医药质量管理协会干细胞与精准医疗质量管理分会、广东省干细胞与再生医学协会会长单位，连续 11 年主办每年一届的国际(广州)干细胞与精准医疗产业化大会，组建粤港澳大湾区干细胞产业联盟，推进国际交流与合作，制定干细胞行业标准，推动干细胞产业高质量发展。公司荣誉“国家知识产权优势企业”、“中国专利优秀奖”、“中国科技创新企业 100 强”、“中国干细胞产业领军企业”、“中国新三板创新百强企业”、“中国最具影响力医药企业百强榜上榜企业”、“广东新三板创新 TOP50 第一名”等称号。